Is pretreatment with Beta-blockers beneficial in patients with acute coronary syndrome?
Details
Serval ID
serval:BIB_26CC4C24C65A
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Is pretreatment with Beta-blockers beneficial in patients with acute coronary syndrome?
Journal
Cardiology
Working group(s)
AMIS Plus Investigators
Contributor(s)
Hess F., Simon R., Hangartner PJ., Rhyner M., Lessing P., Neuhaus M., Hufschmid U., Hunziker P., Grädel C., Schönfelder A., Meier B., Windecker S., Schläpfer H., Evéquoz D., Pampaluchi R., Ciurea-Löchel A., Kruhl M., Vögele A., Ryser D., Müller P., Wüscher V., Jecker R., Niedermaier G., Koelz A., Lederer H., Langenegger T., Haarer J., Schmid HP., Quartenoud B., Moser S., Bietenhard K., Gaspoz JM., Keller PF., Wojtyna W., Schlup P., Oestmann A., Oertli B., Schönenberger R., Simonin C., Waldburger R., Staub P., Schmidli M., Sula P., Weiss EM., Marty H., Zender H., Poepping I., Steffen C., Sollberger J., Hugi A., Koltai E., Pedrazzini G., Erne P., von Meyenburg J., Luterbacher T., Jordan B., Pagnamenta A., Urban P., Feraud P., Beretta E., Stettler C., Repond F., Widmer F., Spillmann A., Scheibe F., Rudaz-Schwaller K., Polikar R., Bassetti S., Iselin HU., Pfister M., Fischer A., Egger P., Kaeslin T., Frey R., Risti B., Stojanovic V., Herren T., Eichhorn P., Flury G., Neumeier C., Hilti P., Grât A., Schöneneberger R., Angehrn W., Rickli H., Yoon S., Loretan P., Stoller U., Veragut UP., Maurer D., Muntwyler J., Hellermann J., Weber A., Garzoli G., Kälin B., Matter H., Schiesser D., Graber M., Haller A., Peter M., Vonesch HJ., Meier HJ., Gasser S., Siegrist P., Fatio R., Vogt M., Ramsay D., Bertel O., Eberli F., Maggiorini M., Bertel O., Eberli F., Brabetz M., Christen S.
ISSN
1421-9751 (Electronic)
ISSN-L
0008-6312
Publication state
Published
Issued date
2010
Volume
115
Number
2
Pages
91-97
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
OBJECTIVES: The role of beta-blockers in the treatment of hypertension is discussed controversially and the data showing a clear benefit in acute coronary syndromes (ACS) were obtained in the thrombolysis era. The goal of this study was to analyze the role of pretreatment with beta-blockers in patients with ACS.
METHODS: Using data from the Acute Myocardial Infarction in Switzerland (AMIS Plus) registry, we analyzed outcomes of patients with beta-blocker pretreatment in whom they were continued during hospitalization (group A), those without beta-blocker pretreatment but with administration after admission (group B) and those who never received them (group C). Major adverse cardiac events defined as composed endpoint of re-infarction and stroke (during hospitalization) and/or in-hospital death were compared between the groups.
RESULTS: A total of 24,709 patients were included in the study (6,234 in group A, 12,344 in group B, 6,131 in group C). Patients of group B were younger compared to patients of group A and C (62.5, 67.6 and 68.4, respectively). In the multivariate analysis, odds ratio for major adverse cardiac events was 0.59 (CI 0.47-0.74) for group A and 0.66 (CI 0.55-0.83) for group B, while group C was taken as a reference.
CONCLUSIONS: beta-Blocker therapy is beneficial in ACS and they should be started in those who are not pretreated and continued in stable patients who had been on chronic beta-blocker therapy before.
METHODS: Using data from the Acute Myocardial Infarction in Switzerland (AMIS Plus) registry, we analyzed outcomes of patients with beta-blocker pretreatment in whom they were continued during hospitalization (group A), those without beta-blocker pretreatment but with administration after admission (group B) and those who never received them (group C). Major adverse cardiac events defined as composed endpoint of re-infarction and stroke (during hospitalization) and/or in-hospital death were compared between the groups.
RESULTS: A total of 24,709 patients were included in the study (6,234 in group A, 12,344 in group B, 6,131 in group C). Patients of group B were younger compared to patients of group A and C (62.5, 67.6 and 68.4, respectively). In the multivariate analysis, odds ratio for major adverse cardiac events was 0.59 (CI 0.47-0.74) for group A and 0.66 (CI 0.55-0.83) for group B, while group C was taken as a reference.
CONCLUSIONS: beta-Blocker therapy is beneficial in ACS and they should be started in those who are not pretreated and continued in stable patients who had been on chronic beta-blocker therapy before.
Keywords
Acute Coronary Syndrome/drug therapy, Acute Coronary Syndrome/mortality, Adrenergic beta-Antagonists/administration & dosage, Aged, Female, Humans, Male, Middle Aged, Switzerland/epidemiology, Treatment Outcome
Pubmed
Web of science
Create date
13/01/2010 14:03
Last modification date
20/08/2019 14:05
Usage data
